A Chester County pharmacy has been fined $1 million and placed on probation by the Pennsylvania Department of State (DOS) for compounding and distributing tens of thousands of injectable weight-loss medications from uninspected facilities.
According to the Department of State, Boothwyn Pharmacy, operating in two buildings on Gale Lane in Kennett Square, began compounding GLP-1 medications in early September 2024. GLP-1 compounds are the active ingredients in popular weight-loss drugs such as Ozempic and Wegovy. The pharmacy reportedly produced over 1,000 doses per day, five days a week.
Investigation Findings
Inspectors discovered that the pharmacy’s main building housed active compounding operations in uninspected rooms. The compounded medications were then transferred to a second building for inspection, verification, packaging, and labeling — even though that second site had not been approved or inspected by the Pennsylvania State Board of Pharmacy for those activities.
Between November 2024 and March 2025, the Department of State conducted four inspections. Investigators reported that the pharmacy staff failed to disclose the ongoing compounding activities and the existence of the unapproved secondary site.
In a consent agreement with the Department of State, Boothwyn Pharmacy admitted to violating the Pennsylvania Pharmacy Act and State Board of Pharmacy regulations. As part of the settlement, the pharmacy placed $500,000 in escrow toward the $1 million penalty. To remove its probationary status, Boothwyn must:
- Pay the remaining $500,000 civil penalty within one year.
- Obtain proper inspection approvals for all facilities.
- Secure Compounding Pharmacy Accreditation from the National Association of Boards of Pharmacy for its compounding operations.
Why the Violations Matter
Compounded drugs are specially prepared medications created by licensed pharmacies to meet individual patient needs. These products are not approved by the U.S. Food and Drug Administration (FDA) and must be produced in sterile, tightly regulated environments. When pharmacies compound or distribute medications in uninspected or unapproved facilities, there is an increased risk of contamination, dosage errors, and mislabeling — all of which can endanger patient health.
The state’s enforcement action comes amid growing scrutiny of compounded GLP-1 medications, which have surged in demand alongside brand-name drugs such as Ozempic, Wegovy, and Mounjaro. Regulators have emphasized that any large-scale compounding of injectable medications requires strict oversight to protect patients from unsafe or contaminated products.
What Consumers Should Do
Patients who obtained compounded medications from Boothwyn Pharmacy or any pharmacy under investigation should:
- Review prescription details and batch information for their compounded drugs.
- Consult their physician before discontinuing use and seek medical advice if they experience side effects.
- Report adverse reactions or product concerns to the Pennsylvania Department of State and the FDA’s MedWatch reporting system.
Legal Options for Affected Consumers
Consumers harmed by improperly compounded or distributed medications may have legal grounds to pursue product liability or negligence claims against the pharmacy or other responsible parties. Potential damages can include medical costs, lost wages, pain and suffering, and punitive damages where reckless conduct is proven.
A Chester County Product Liability Lawyer at Samuel Anyan Attorney At Law Fights for Clients Harmed by Dangerous Drugs
Improperly compounded medications can have serious and lasting consequences for unsuspecting consumers. If you or a loved one has been harmed by a dangerous or defective drug, an experienced Chester County product liability lawyer at Samuel Anyan Attorney At Law can help. Call 833-372-6946 or contact us online to schedule a free consultation. Located in Philadelphia, we proudly serve clients throughout the surrounding areas.